Abstract：
UNASSIGNED: Triple-negative breast cancer (TNBC) accounts for 15-20% of breast cancers (BC) and has the worst prognosis. It is characterized by the absence of both hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2). TNBC has more limited therapeutic options compared to other subtypes, meaning that there is still a long way to go to discover target treatments.
UNASSIGNED: Our review aims to summarize phase II/III clinical trials enrolling patients with TNBC that have been published between 2017 and 2022 but failed to reach their primary endpoint. We here try to emphasize the limitations and weaknesses noted in negative studies and to point out unexpected results which might be useful to enhance the therapeutic approach to TNBC disease.
UNASSIGNED: A deeper understanding of the mechanisms behind TNBC heterogeneity allowed to enhance the knowledge of new prognostic and predictive biomarkers of response. However, it is also through several failed clinical trials that we were able to define new therapeutic approaches which improved TNBC patients\' clinical outcomes. Nowadays, we still need to overcome several difficulties to fully recognize different intracellular and extracellular pathways that crosstalk in TNBC and the mechanisms of resistance to identify novel tailored-patients\' therapies.
UNASSIGNED: Our review aims to summarize phase II/III clinical trials enrolling patients with TNBC that have been published between 2017 and 2022 but failed to reach their primary endpoint. We here try to emphasize the limitations and weaknesses noted in negative studies and to point out unexpected results which might be useful to enhance the therapeutic approach to TNBC disease.
UNASSIGNED: A deeper understanding of the mechanisms behind TNBC heterogeneity allowed to enhance the knowledge of new prognostic and predictive biomarkers of response. However, it is also through several failed clinical trials that we were able to define new therapeutic approaches which improved TNBC patients\' clinical outcomes. Nowadays, we still need to overcome several difficulties to fully recognize different intracellular and extracellular pathways that crosstalk in TNBC and the mechanisms of resistance to identify novel tailored-patients\' therapies.
摘要：
未经证实：三阴性乳腺癌（TNBC）占乳腺癌（BC）的15-20％，预后最差。其特征在于不存在激素受体(HR)和人表皮生长因子受体2(HER2)。与其他亚型相比，TNBC的治疗选择更有限，这意味着要发现目标治疗还有很长的路要走。
UNASSIGNED：我们的综述旨在总结在2017年至2022年间发表但未能达到主要终点的TNBC患者的II/III期临床试验。我们在此尝试强调阴性研究中指出的局限性和弱点，并指出可能对增强TNBC疾病的治疗方法有用的意外结果。
UNASSIGNED：对TNBC异质性背后的机制的更深入了解可以增强对新的预后和预测性反应生物标志物的认识。然而,也是通过几个失败的临床试验,我们能够确定新的治疗方法,改善TNBC患者的临床结局.如今,我们仍然需要克服几个困难,以充分识别TNBC中不同的细胞内和细胞外途径的串扰以及耐药机制,从而确定新的定制患者疗法.
UNASSIGNED：我们的综述旨在总结在2017年至2022年间发表但未能达到主要终点的TNBC患者的II/III期临床试验。我们在此尝试强调阴性研究中指出的局限性和弱点，并指出可能对增强TNBC疾病的治疗方法有用的意外结果。
UNASSIGNED：对TNBC异质性背后的机制的更深入了解可以增强对新的预后和预测性反应生物标志物的认识。然而,也是通过几个失败的临床试验,我们能够确定新的治疗方法,改善TNBC患者的临床结局.如今,我们仍然需要克服几个困难,以充分识别TNBC中不同的细胞内和细胞外途径的串扰以及耐药机制,从而确定新的定制患者疗法.
